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Introduction: We sought to evaluate the clinical and pathological 
characteristics of patients with non–small-cell lung cancer (NSCLC) 
that harbored a ROS1 rearrangement.
Methods: Four hundred fifty-one Korean patients with resected 
NSCLC (the resected group) were examined for ROS1 rearrange-
ments using a tissue microarray and ROS1 fluorescence in situ 
hybridization and analyzed for clinical and pathological features. 
Sixty-four patients with advanced pulmonary adenocarcinoma with 
no known oncogenic aberrations (the advanced group) were also 
screened for ROS1 rearrangements.
Results: Of the 451 consecutive patients from the resected group, 
ROS1 rearrangements were detected in eight cases (1.8%). In the 
advanced group, an additional eight patients (12.5%) were identi-
fied as harboring ROS1 rearrangements. ROS1 rearrangement was 
detected exclusively in adenocarcinomas and occurred more fre-
quently in women than in men. With the exception of one patient 
with an EGFR deletion mutation in exon 19, ROS1-positive adeno-
carcinomas in all patients revealed no alterations in ALK, EGFR, 
KRAS, or MET genes. Most ROS1-rearranged tumors showed solid 
and papillary patterns.
Conclusions: ROS1 rearrangements were detected in 1.8% of 
patients with resected NSCLC and were detected exclusively in 
adenocarcinomas, which is similar to the frequency detected in non-
Asian patients. We suggest that ROS1 screening in adenocarcinoma 
patients with no known oncogenic aberrations is an effective strategy 
to find ROS1 rearrangements in NSCLC.
Key Words: Pulmonary adenocarcinoma, ROS1, Fluorescence in 
situ hybridization, Clinicopathology, Molecular enrichment strategy.
(J Thorac Oncol. 2013;8: 1445–1450)
Patients with non–small-cell lung cancer (NSCLC) har-boring either EGFR mutations or ALK rearrangements 
were recently reported to have significantly better responses 
to treatment with specific tyrosine kinase inhibitors (TKIs).1,2 
The therapeutic success of TKIs for lung cancer patients has 
motivated the identification of aberrations in novel kinases 
and the development of specific inhibitors that target individ-
ual tumors. As a result, several novel driver oncogenes have 
been demonstrated in NSCLC.3,4
ROS1 is a newly identified gene-rearranged oncogenic 
receptor tyrosine kinase,4 and the ROS1 fusion protein was 
demonstrated to have transforming potential in nude mice5 
with NSCLC. Recently, Bergethon et al.6 suggested that 
ROS1 rearrangements define a unique molecular classification 
of lung cancer with distinct clinical characteristics, such as 
a response to crizotinib. They also showed that ROS1 rear-
rangements were detected in 1.7% of NSCLC patients, and 
the patients tend to be younger never-smokers with adenocar-
cinomas. Furthermore, Bergethon et al. suggested that ROS1 
rearrangements were more common in Asians. However, in 
subsequent studies, ROS1 rearrangement was not found to be 
more prevalent in Asian and younger patients and was also 
detected in squamous cell carcinoma.5,7,8 Overall, the accu-
rate incidence and clinicopathologic characteristics of ROS1-
rearranged tumor remain unclear.
Therefore, we aimed to characterize the clinicopatho-
logical features of ROS1-rearranged NSCLC in a Korean pop-
ulation and to propose a diagnostic algorithm to detect ROS1 
rearrangements.
PATIENTS AND METHODS
Four hundred fifty-one consecutive Korean patients with 
NSCLC who underwent resection at the Seoul National University 
Hospital between 1997 and 2008 were selected, and we con-
structed a 2-mm diameter tissue microarray for these patients, 
who were designated as the resected group. Sixty-four patients 
with recurrent or metastatic pulmonary adenocarcinomas were 
designated as the advanced group. EGFR and ALK genes were 
wild types in all the advanced group patients and KRAS and BRAF 
genes were also wild types in all tested patients (KRAS, n = 62; 
BRAF, n = 24) of the advanced group. All of the advanced group 
patients were screened for ROS1 rearrangements as part of the 
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ongoing crizotinib phase 1 study (NCT00585195). The eligible 
patients who were confirmed to have ROS1-positive advanced 
NSCLC were given the option for crizotinib therapy in the clini-
cal trial. The outcomes of these patients will be reported later. 
This study was approved by the Institutional Review Board of 
Seoul National University Hospital (IRB No.: H-1210-073-
434). Histopathology of all tumors was reviewed by two pathol-
ogists (HG and DHC), classified using the 2011 International 
Association for the Study of Lung Cancer/American Thoracic 
Society/european Respiratory Society criteria, and staged 
according to the American Joint Committee on Cancer tumor, 
node, metastasis criteria, 7th edition.
Fluorescence in situ hybridization (FISH) was performed 
with the following probes: ROS1 rearrangement, bronchoalve-
olar carcinoma clone corresponding to the 5′ (RP11-835I21) 
and 3′ (RP11-1036C2) ends was kindly provided by Professor 
Anthony John Iafrate6; ALK inversion, locus-specific identi-
fier dual-color break-apart probes (Vysis; Abbott Molecular, 
Abbott Park, IL); gene copy number of EGFR and c-MET, 
EGFR/CEP7 (Vysis; Abbott Molecular); and MET/CEP7 
(Kreatech Diagnostics, Amsterdam, The Netherlands). FISH-
positive ROS1 and ALK genes were defined as more than 15% 
of tumor cells showing split or isolated red signals. The posi-
tivity for gene copy number of EGFR and MET were defined 
as high gene copy with high polysomy or gene amplifications.9 
Sanger’s sequencing was performed for EGFR (exons 18–21), 
KRAS (exon 2), and BRAF (exon 15), as described previ-
ously.10,11 Reverse transcriptase polymerase chain reaction 
was performed using the primers described by Takeuchi et al.5 
Statistical analysis was conducted using IBM-SPSS Statistics 
software 19.0 (IBM Corp., New York, NY).
RESULTS
Examination of ROS1 Rearrangements in NSCLC
ROS1 rearrangements were identified in 16 patients 
with NSCLC using FISH (Table 1). ROS1-negative cases 
showed two fused yellow signals or closely apposed green 
and red signals (Fig. 1A). ROS1-rearranged tumor nuclei 
showed two patterns: (1) break-apart green and red (split; 
Fig. 1B) or (2) an isolated red (Fig. 1C). In ROS1-positive 
patients (n = 16), a split pattern was observed in 14 tumors 
(87.5%), and an isolated red pattern was observed in two 
tumors (12.5%). The formalin-fixed, paraffin-embedded 
FIGURE 1. ROS1 FISH patterns of lung 
adenocarcinomas. A, Tumor cell nuclei with 
wild-type ROS1 showed nonsplit of two yel-
low or closely apposed green and red sig-
nals. B, ROS1-rearranged cases with a split 
pattern showed a pattern with more than a 
one-signal-size split between green and red 
signals. C, ROS1-rearranged cases with iso-
lated 3′ ends showed one or more isolated 
red signals and intact fusion signals. FISH, 
fluorescence in situ hybridization.
TABLE 1.  Screening of ROS1 Rearrangement of PatientsM with the Use of FISH
No. of Screened Tumors FISH Pattern of ROS1-Rearranged Tumors
ROS1-Positive ROS1-Negative
Total Number p
Split Pattern Single 3′ Pattern
Total  
Numbern % n % n % n %
Resected groupa 8 1.8 443 98.2 451 <0.001 8 100 0 0 8
Advanced groupb 8 12.5 56 87.5 64 6 75 2 25 8
aConsecutive patients.
benriched by adenocarcinoma histology and no known molecular alterations in EGFR, ALK, KRAS, or BRAF.
FISH, fluorescence in situ hybridization.
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tissues were available for reverse transcriptase polymerase 
chain reaction in 11 of 16 cases, and bands were detected 
in only three cases, of which two were CD74-ROS1 and one 
was TPM3-ROS1.
Clinical and Molecular Features of ROS1-
Rearranged NSCLC in the Resected Group
Clinicopathologic features of NSCLC patients accord-
ing to the ROS1 rearrangement are summarized in Table 2. 
TABLE 2.  Relationship between ROS1 FISH and Clinicopathologic Features of NSCLC Patients
No. of Patients
ROS1 Rearrangement
p
Positive Negative
n % n % n %
Resected group 451 100 8 100 443 100
 Sex
  Male 316 70.1 3 37.5 313 70.7 0.042
  Female 135 29.9 5 62.5 130 29.3
 Age
  Median (range), yr 61.99 (34–87) 59.00 (39–80) 62.00 (34–87) 0.369
 Smoking status
  Never-smoker 163 36.1 5 62.5 158 35.7 0.117
  Smoker 288 63.9 3 37.5 285 64.3
 Histology
  Adenocarcinoma 236 52.3 8 100 228 51.5 0.024
  Squamous cell 
carcinoma
167 37.0 0 0 167 37.7
  Other 48 10.6 0 0 48 10.8
 Stage group
  I 219 48.6 4 50.0 215 48.5 0.502
  II 126 27.9 1 12.5 125 28.2
  III 106 23.5 3 37.5 103 23.3
 ALK BA FISH 434 100 8 100 426 100
  Positive 14 3.2 0 0 14 3.3 1.000
  Negative 420 96.8 8 100 412 96.7
 ALK IHC 433 100 8 100 425 100
  Positive 15 3.5 0 0 15 3.5 1.000
  Negative 418 96.5 8 100 410 96.5
 EGFR mutation 358 100 6 100 352 100
  Mutant type 103 28.8 1 11.1 102 29.0 0.678
  Wild type 255 71.2 5 55.6 250 71.0
 EGFR FISH 441 100 8 100 433 100
  Amplification 31 7.0 1 12.5 30 6.9 0.345
  High polysomy 85 19.3 0 0 85 19.6
  Negative 325 73.7 7 87.5 318 73.4
 c-MET FISH 197 100 2 100 195 100
  Positive 13 6.6 0 0 13 6.7 0.706
  Negative 184 93.4 2 100 182 93.3
Advanced group 64 100 8 100 56 100
 Sex
  Male 33 51.6 1 12.5 32 57.1 NT
  Female 31 48.4 7 87.5 24 42.9
 Age
  Median (range) 58.94 (28–84) 50.00 (34–78) 60.21 (28–84) NT
 Smoking 59 100 6 100 53 100
  Never-smoker 31 52.5 5 83.3 26 49.1 0.198
  Smoker 28 47.5 1 16.7 27 50.9
BA, break apart; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NT, not tested; NSCLC, non–small-cell lung cancer.
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ROS1-rearranged NSCLCs of the resected group were exclu-
sively adenocarcinomas (p = 0.024) and were predominantly 
found in women (p = 0.042). Among the adenocarcinomas, the 
incidence of ROS1 rearrangements was 3.4%. The mean age 
of ROS1-positive cases was lower than that of ROS1-negative 
cases, but this difference was not significant (p = 0.369; 
Table 2). All tested known driver oncogenes, including ALK, 
EGFR, and MET, were mutually exclusive with ROS1 rear-
rangements except in one case. The patient was a 59-year-old 
woman with adenocarcinoma showing ROS1 rearrangement 
as well as EGFR mutation (e746-A750 deletion) and EGFR 
gene amplification (Table 3).
Clinical Features of ROS1-Rearranged 
Pulmonary Adenocarcinomas 
in the Advanced Group
Patients in the advanced group were selected for the 
ROS1 FISH study according to previous histologic assess-
ments and the status of driver oncogenic aberrations and 
stages. Those patients who showed adenocarcinoma histology 
and had advanced stages (stage IIIB-IV) or recurrence, but 
harbored no known genetic aberrations were included. The fre-
quency of ROS1 rearrangement of advanced group enriched by 
adenocarcinoma histology and no known molecular alterations 
in EGFR, ALK, KRAS, or BRAF, was significantly higher than 
that in resected group, which was consecutive cases of NSCLCs 
(12.5% versus 1.8%,  respectively; p < 0.001; Table 2).
Histological Features of ROS1-Rearranged Tumors
Fourteen of 16 ROS1-rearranged cases were classifiable 
in terms of histopathologic patterns. ROS1-rearranged tumors 
showed heterogenous patterns of adenocarcinoma; however, 
solid and micropapillary patterns were frequently observed in 
at least the focal areas of tumors in 78.5% (11 of 14) of the 
cases (Table 3). Solid, papillary, and micropapillary patterns 
were detected in 64.3%, 14.3%, (Fig. 2A, B) and 50.0% of 
the cases, respectively. Signet-ring cells and mucinous cribri-
form patterns were detected in 14.3% and 7.1% of the cases, 
respectively (Fig. 2C, D). However, a lepidic pattern was 
focally detected in only one case.
TABLE 3.  Clinicopathologic Features of Patients with ROS1-Rearranged NSCLCs
Resected group
No. Sex Age
Smoking 
Status (PY) ALK FISH
EGFR 
Sequencing EGFR FISH c-MET FISH
Stage 
Group
Histologic 
Diagnosis Histologic Patternb
 1 Female 57 Never-smoker Negative NA Negative NA IIIA ADC Solid
 2 Female 57 Never-smoker Negative NA Negative NA IA ADC Acinar, papillary, 
micropapillary
 3 Female 80 Never-smoker Negative Negative Negative Negative IA ADC Solid, acinar, papillary
 4 Male 55 ex-smoker 
(30)
Negative Negative Negative Negative IA ADC Acinar, lepidic
 5 Male 69 ex-smoker 
(50)
Negative Negative Negative NA IIIA ADC Solid, acinar
 6 Female 39 Never-smoker Negative Negative Negative NA IIIA ADC Papillary
 7 Male 56 ex-smoker 
(NA)
Negative Negative Negative NA IIA ADC NA
 8 Female 59 Never-smoker Negative e746-A750 
deletion
Amp NA IB ADC Papillary, acinar, solid
Advanced group
No. Sex Age Smoking 
Status (PY)
ALK- 
Rearrangementa
EGFR 
Sequencing
KRAS 
Sequencing
BRAF 
Sequencing
Stage 
Group
Histologic 
Diagnosis
Histologic Patternb
 9 Male 34 NA Negative Negative NA Negative IVB ADC Solid, signet-ring cells
 10 Female 39 Never-smoker Negative Negative Negative Negative IVB ADC Solid, papillary, Acinar
 11 Female 44 Never-smoker Negative Negative Negative Negative Recurrent ADC Papillary, mucinous 
cribriform, 
micropapillary
 12 Female 43 Never-smoker Negative Negative Negative Negative Recurrent ADC Solid, papillary
 13 Female 61 ex-smoker 
(35)
Negative Negative Negative NA IVB ADC Signet-ring cells
 14 Female 52 NA Negative Negative NA NA IVB ADC NA
 15 Female 78 Never-smoker Negative Negative Negative Negative IIIB ADC Solid
 16 Female 49 Never-smoker Negative Negative Negative Negative IVB ADC Solid
aALK-rearrangement was screened by both ALK IHC and ALK BA FISH in all cases.
bArranged in order of predominance.
PY, pack year; NA, not applicable; Amp, amplification; ADC, adenocarcinoma; NSCLCs, non–small-cell lung cancers; FISH, fluorescence in situ hybridization.
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DISCUSSION
We examined ROS1 rearrangements with the use of FISH 
and the clinicopathologic implications of ROS1-rearranged 
tumors in NSCLC. Our data demonstrated that ROS1-rearranged 
tumors were exclusively adenocarcinomas and were predomi-
nantly observed in women, which is consistent with previous 
reports.5,6 ROS1 rearrangements are almost mutually exclusive 
of other oncogenic aberrations. Interestingly, one case had 
both ROS1 and EGFR alterations. Rimkunas et al.7 also identi-
fied two cases of NSCLC, with either a ROS1-positive/EGFR 
L858R mutation or a ROS1-positive/EGFR e746-A750 dele-
tion. The biological implications of concomitant alterations of 
driver oncogenes in NSCLCs remain unclear.
With the use of FISH, Bergethon et al.6 reported that ROS1-
rearranged tumors were present in 1.3% of non-Asian patients 
and 10% of Asian patients, indicating that ROS1 rearrangements 
are more frequently detected in Asian patients than in non-
Asians. However, one report demonstrated that the incidence 
of ROS1-rearranged NSCLC was only approximately 0.9% in 
Japanese patients using FISH,5 and another study detected ROS1 
immunoreactivity in 1.6% of Chinese patients.7 Our data dem-
onstrated that the incidence of ROS1 rearrangements in NSCLC 
was 1.8%, which is similar to that reported for Chinese patients 
but higher than that reported for Japanese patients. Furthermore, 
the same FISH probes used by Bergethon et al. were used in 
this study to assess ROS1 rearrangements. Therefore, the inci-
dence of ROS1 rearrangements in Korean patients with NSCLC 
is much lower than that reported by Bergethon et al. Taken 
together, these data demonstrate that ROS1 rearrangements in 
patients with NSCLC might not be more frequent in Asian popu-
lations than in non-Asian populations.
Recently, several researchers sought to find novel genetic 
alterations other than EGFR, KRAS and ALK in pulmonary ade-
nocarcinomas. However, many genes are mutated in NSCLC, 
and the incidence of novel mutations is very low.12 Moreover, 
driver oncogenic mutations are mutually exclusive in general,13 
and effective TKIs have been used in NSCLC patients with 
EGFR mutation or ALK translocation. According to recently 
published data, 23.5% to 40% of pulmonary adenocarcinomas 
were EGFR-/KRAS-/ALK-, designated as triple negative,12,14 
facilitating the estimation of ROS1-rearranged tumor inci-
dence in pulmonary adenocarcinomas among Korean patients. 
Calculations based on those data showed that the expected 
detection frequency of ROS1-rearranged adenocarcinomas 
ranged from 8.5% to 14.5% among EGFR-/KRAS-/ALK- pul-
monary adenocarcinomas in Korean patients. In this study, all 
adenocarcinoma patients in the advanced group had wild-type 
EGFR, KRAS, and ALK, except two patients, who had unknown 
KRAS status, whereas genetic alterations were not examined 
before the ROS1 FISH test in the resected group. The incidence 
of ROS1 rearrangements in the advanced group was signifi-
cantly higher than that in the resected group (p < 0.001), indi-
cating that the triple negative adenocarcinoma–selected ROS1 
FISH test is an effective strategy to find ROS1 rearrangements 
in NSCLC. Therefore, we suggest that a molecular-enrichment 
algorithm for ROS1 rearrangements (SNUH molecular-enrich-
ment strategies), which is shown in Figure 3.
Yoshida et al.15 proposed that the EML4-ALK oncogenic 
process might be a critical contributor to the development of 
ALK-rearranged NSCLCs rather than preinvasive lesions in 
the lungs. Similar to ALK translocations in NSCLC, ROS1-
rearranged pulmonary adenocarcinomas frequently showed 
high-grade histological patterns, such as solid and micropap-
illary patterns, but rarely showed a lepidic pattern, leading to 
the hypothesis that ROS1 may be a strong oncogenic driver 
in NSCLCs. Furthermore, we suggest that solid and papillary 
patterns might be characteristic features of ROS1-rearranged 
adenocarcinomas.
In summary, ROS1-rearranged adenocarcinomas were 
found in 1.8% of patients with NSCLCs, similar to the 
FIGURE 2.  Pathologic features of a case 
with ROS1 rearrangements. A, Solid pat-
tern, (B) micropapillary pattern, (C) signet-
ring cell component, and (D) mucinous 
cribriform pattern.
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frequencies observed in patients from non-Asian countries. 
ROS1 screening in adenocarcinoma patients with no known 
oncogenic mutations might be an effective strategy to find 
ROS1 rearrangements in NSCLC.
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FIGURE 3.  Seoul National University Hospital molecular 
enrichment strategies for ROS1 rearrangements. Histologic 
examination of NSCLC has to be preceded with biopsy, 
resection, or cytologic specimens before molecular tests for 
confirming adenocarcinoma. After screening for mutations of 
EGFR and KRAS and the fusion of ALK, the triple negative ade-
nocarcinomas–selected ROS1 FISH test seemed to be effective 
for finding ROS1 rearrangements. NSCLC, non–small-cell lung 
cancer; FISH, fluorescence in situ hybridization; TKI, tyrosine 
kinase inhibitor.
